LCD L39005: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Noridian
Policy LCD-L39005 · Oncology
New LCD for prostate cancer biomarkers impacts billing strategies.
Code intelligence
C61 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code C61.
Elevated code riskView ICD-10 detail
Signal breakdown
36 shown · 36 total in platform
Risk: Elevated
0
Critical
0%
10
High
28%
25
Routine
69%
1
Low
3%
New this month
+3
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
High
LCD L39553: Radiation Therapies — Palmetto GBA
Policy LCD-L39553 · Oncology
New LCD may impact radiation therapy billing practices.
LCD L39007: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Noridian
Policy LCD-L39007 · Oncology
New LCD for prostate cancer risk-stratification impacts billing.
LCD L38985: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Palmetto GBA
Policy LCD-L38985 · Oncology
New MolDX requires billing team review.
LCD L38997: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — CGS
Policy LCD-L38997 · Urology
New LCD for prostate cancer biomarkers impacts billing.
LCD L40278: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in Cancer — WPS
Policy LCD-L40278 · Oncology
WPS final LCD on non-NGS molecular panel tests for cancer therapy—eff. 10/12/26
LCD L40210: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in Cancer — Palmetto GBA
Policy LCD-L40210 · Oncology
Palmetto finalizes coverage for non-NGS molecular panel cancer tests, eff. 10/12
LCD L40222: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in Cancer — Noridian
Policy LCD-L40222 · Clinical Laboratory
Noridian finalizes non-NGS cancer panel test coverage rules eff. 10/12/2026
Proposed LCD DL40226: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer — CGS
Policy LCD-DL40226 · Oncology
Proposed LCD on targeted molecular tests may affect oncology billing.
LCD L38292: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease — Palmetto GBA
Policy LCD-L38292 · Oncology
New genomic assay coverage requires billing team review.
LCD L39232: MolDX: Plasma-Based Genomic Profiling in Solid Tumors — Noridian
Policy LCD-L39232 · Oncology
New genomic profiling coverage supports compliance with updated rates.
Proposed LCD DL40222: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer — Noridian
Policy LCD-DL40222 · Oncology
Impact on billing for targeted molecular panel tests.
LCD L38341: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease — Noridian
Policy LCD-L38341 · Oncology
New Genomic Classifier Assay impacts prostate cancer billing.
LCD L38814: MolDX: Minimal Residual Disease Testing for Cancer — Noridian
Policy LCD-L38814 · Oncology
Billing impact from new MolDX LCD for cancer tests.
LCD L38643: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells — Noridian
Policy LCD-L38643 · Oncology
New billing guidelines for circulating tumor cells from 2026.
LCD L39017: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer — CGS
Policy LCD-L39017 · Oncology
New LCD impacts billing for inherited cancer testing services.
LCD L39040: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer — WPS
Policy LCD-L39040 · Oncology
Updates on lab tests for inherited cancer syndromes effective April 2024.
LCD L37620: MDS FISH — Noridian
Policy LCD-L37620 · Clinical Laboratory
New MDS FISH LCD will affect billing from 10/23/2025.
LCD L37630: In Vitro Chemosensitivity & Chemoresistance Assays — Noridian
Policy LCD-L37630 · Oncology
New LCD impacts oncology billing for lab assays.
LCD L38119: MolDX: Next-Generation Sequencing for Solid Tumors — Noridian
Policy LCD-L38119 · Oncology
New billing guidelines for solid tumors effective 02/05/2026.
LCD L38339: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease — Noridian
Policy LCD-L38339 · Oncology
New assay coverage may influence prostate cancer billing practices.
LCD L36658: Proton Beam Therapy — CGS
Policy LCD-L36658 · Oncology
Proton Beam Therapy requires billing team review-2025.
LCD L38678: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells — WPS
Policy LCD-L38678 · Oncology
Prepare for new billing guidelines effective July 2025.
LCD L35076: Stereotactic Radiation Therapy: Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) — Wellpoint Federal
Policy LCD-L35076 · Radiology
Final LCD sets SRS/SBRT coverage rules under Part A & B eff. 4/1/2026
LCD L35986: Special Histochemical Stains and Immunohistochemical Stains — CGS
Policy LCD-L35986 · Clinical Laboratory
New LCD affects billing for histochemical stains.
LCD L39284: Prostate Cancer Detection with IsoPSA® — CGS
Policy LCD-L39284 · Urology
New IsoPSA code impacts prostate cancer billing guidelines.
LCD L38121: MolDX: Next-Generation Sequencing for Solid Tumors — Noridian
Policy LCD-L38121 · Oncology
compliance updates with MolDX for oncology testing.
LCD L37602: MDS FISH — Palmetto GBA
Policy LCD-L37602 · Clinical Laboratory
New MDS FISH LCD may impact billing practices in 2026.
LCD L38972: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer — Noridian
Policy LCD-L38972 · Oncology
New LCD affects billing for inherited cancer tests.
LCD L39686: MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers — Noridian
Policy LCD-L39686 · Oncology
Key updates for prostate cancer decision-making tests.
LCD L39688: MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers — Noridian
Policy LCD-L39688 · Urology
New guidelines impact billing for prostate cancer tests.
LCD L35075: Proton Beam Therapy — Wellpoint Federal
Policy LCD-L35075 · Oncology
Wellpoint Final LCD: Proton Beam Therapy coverage criteria effective 4/1/2026
LCD L33578: Transrectal Ultrasound — Wellpoint Federal
Policy LCD-L33578 · Radiology
Wellpoint Final LCD: Transrectal Ultrasound coverage criteria effective 4/1/26
LCD L37810: Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms — NGS
Policy LCD-L37810 · Oncology
NGS LCD covers genomic panels for solid tumor Tx in NY, CT, MA & more.
LCD L33826: Oral Anticancer Drugs — DME MAC
Policy LCD-L33826 · Oncology
DME MAC LCD for oral anticancer drugs effective Jan 1, 2026.
LCD L40205: Irreversible Electroporation for Cancer — Palmetto GBA
Policy LCD-L40205 (Notice Ends 07/04/2026) · Oncology
Palmetto GBA finalizes IRE cancer coverage rules effective 07/05/2026.
Audit documentation
Building an audit file that includes C61?
The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Oncology audit pack — $349One-time purchase · not a subscription